- Enrolling Phase 1 study of lead NBD1 modulator, SION-638, following IND clearance from the FDA; data expected in the second half of 2023 - - SION-109, targeting complementary mechanism ICL4, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results